PPT-Developing Better Medicines at Lower

Costs The Good Pharma Model Speaker Donald W Light Visiting Professor Cambridge University Dept of Sociology Discussant Professor Alistair McGuire Chair LSE Health Chair Professor . Die Cirkulation von Dampfern. Rauch. Pp. Ueber Emission und Absorptiou Wiirnie onrl Ungarn. Pp. oberen Schari meteorologischen Beobachtungen zu Guatemala Magnetische Eleniente Bericht iiber die intern Global context of drug regulation. Dr Lembit Rägo. Coordinator. Quality Assurance and Safety: Medicines. Essential Medicines and Health Products. World Health Organization. E-mail: . ragol@who.int. Thalidomide was found to be unsafe for pregnant women as it affected their developing foetuses. Many women who took the drug gave birth to babies with severe limb deformities. . Later on Doctors discovered thalidomide could cure leprosy and started for patient suffering with the disease in the developing world. But again children were born with abnormalities.. Cochin University of Science & Technology . Sakthivel. . Selvaraj. Public Health Foundation of India . New . Delhi . (shakti@phfi.org). Access to Medicines in India . Key Barriers to . Access to Medicines . Drugs . Developing new medicines . How effective are medicines . Legal and illegal. drugs . Drugs in sport . Cannabis. and hard drugs . Developing new medicines . A good medicine is:. Effective . – prevent / cure a disease / ease symptoms . EMP - Technical Briefing Seminar. . 1 November, 2013. WHO HQ, Geneva. Zafar . Mirza. Public . Health, Innovation and Intellectual . Property Unit. Essential Medicines & Health Products Department . Costs: The . Good Pharma Model. Speaker:. Donald W. Light. Visiting Professor, Cambridge University, . Dept. of Sociology . Discussant: . Professor Alistair McGuire . Chair, LSE Health. Chair: . Professor . By Laura Christian, Linda Collins, . Maythiwan. . Kiatgrajai. , . Agathe. Merle, . Nayantara. . Mukherji. , Alissa . Quade. Outline. Methodology. Overview. Definitions. Harmful Effects. Extent of the Problem. EMP - Technical Briefing Seminar. . 1 November, 2013. WHO HQ, Geneva. Zafar . Mirza. Public . Health, Innovation and Intellectual . Property Unit. Essential Medicines & Health Products Department . By Laura Christian, Linda Collins, . Maythiwan. . Kiatgrajai. , . Agathe. Merle, . Nayantara. . Mukherji. , Alissa . Quade. Outline. Methodology. Overview. Definitions. Harmful Effects. Extent of the Problem. Once . the protection of the product . expires for . example, patents or regulatory protection such as data . exclusivity, . the company no longer has exclusive rights to sell the medicine. . Other . TRADING AWAY HEALTH: THE TRANS-PACIFIC PARTNERSHIP AGREEMENT (TPP) MSF Access Campaign Médecins Sans Frontières, Rue de Lausanne 78, CP 116, CH-1211 Geneva 21, Switzerland Tel: + 41 (0) 22 849 84 Medicines Manufacturing in the UK 2017. Welcome by Andy Evans. Chair, MMIP. Site Lead, AZ Macclesfield. Morning Agenda. 10:00. Introduction. Steve. Thompson ABPI. Steve Bates BIA. Sue Dunkerton KTN. Basic enquiry answering. September . 2016. Session aims. Increase awareness of the Medicines Information (MI) services. UK. Wales. Increase awareness of the questions to ask an enquirer. Have practical experience using some resources which will be...